116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2
Junji Furuse, Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Robin Kate Kelley, Philippe A. Cassier, H.-J. Klümpen, N. Uboha, Amit Mahipal, Edith P. Mitchell, Eugene R. Ahn, H.-M. Chang, Kunihiro Masuda, Yi He, Karim A. Benhadji, John Bridgewater
Topics & Concepts
MedicineInternal medicineClinical endpointAdverse effectQuality of life (healthcare)Intrahepatic CholangiocarcinomaGastroenterologyOncologyProgression-free survivalSurgeryChemotherapyClinical trialNursingCholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchPancreatic and Hepatic Oncology Research